Innovative new private script solution simplifies access to medicines for HCPs, patients and hospital pharmacies

Change in Country Leadership with an internal promotion while the current GM moves to a big role in the UK

Oncology pharma officially adopts its new name and new logo in ANZ as part of a phased rollout around the world

Busy week for growing franchises as Phebra becomes the first company to register a copycat of a Pfizer drug

Current head promoted to a regional role overseeing 11 countries with a successor for the ANZ job already named

Calls to release the full Medical Research Future Fund allocation which has over $1 billion available this year

Up to 3,000 jobs will be cut and Seqirus to become a standalone company as CSL looks to cut complexity, saving $500 million a year

Supply constraints relating to this PBS listed medicine are expected to hit Australia this month and continue for all of 2025

See who's landed a new role across industry, with three execs moving on after more than a decade at the same company

Collaboration with Monash University aims to transform disease management and improve outcomes for patients

Negotiations with Europe aim to 'rebalance' prices but Lilly remains tight-lipped on specific implications for Australia

Aimed at Aussie early to mid-career women in STEM, it offers recognition, funding and induction to an alumni network

After rising the ranks to run the company's US business, this former ANZ Country Leader will finish up at the end of the year

ICYMI: Company names replacement for departing MD plus the other most popular stories this week

Find out who's a step closer to adding new indications to their drugs after the TGA accepted their applications for review

Notifies the TGA that it will gradually discontinue some of its earlier generation insulin products with the process already underway

Research funded by Diabetes Australia will be guided by those with lived experience under a new plan

Shortages of both strengths of the PBS listed medicine expected to last until the end of 2025, although the higher dose will be more readily available